11 Comments

Molnupiravir was developed at Emory, who are in bed with the CDC, I'm sure there are absolutely no conflicts of interest.

It seems our entire healthcare system is one big grift.

Expand full comment

Very interesting!!!

Expand full comment

Air hammer

Expand full comment

Forged by dwarves.

Expand full comment

Evildwarves.

Expand full comment

We should not be too terribly surprised by instances of rebound infection beyond Paxlovid. Rebound infection from COVID-19 was a known phenomenon even before the mRNA inoculations.

https://allfactsmatter.substack.com/p/cdc-issues-paxlovid-warning-but-what

However, what has been noted with Paxlovid appears to be that rebound infection is more common among the inoculated than the non-inoculated. Given that Paxlovid itself would work the same in both patient cohorts, that variance is a strong signal of immunological damage from the mRNA inoculations.

Elevated cases of rebound infection among COVID patients treated with Molnupiravir arguably sends the same signal.

Where the efficacy of the drug is inherently suspect, elevated instances of rebound infection among inoculated patients should be the expected scenario, so far as I can tell.

Expand full comment

Yes. The important part here is that those taking Molnupiravir are rebounding at the same (or higher) rate as with Paxlovid, which has been established to be well above baseline

Expand full comment

I'm trying real hard to be shocked by all of this. Really, I am.

At this point it's becoming hard to avoid the inevitable cynicism. We're so far past any reasonable debate over the toxicity of both the mRNA inoculations and these poisonous concoctions masquerading as therapies that the only real question is when do we apply a dose of tar and feathers to the FDA and CDC "experts" pushing this crap on the people?

Expand full comment

I think it's a good wake up calling a way. I remember Toby Rogers pointed out the vast majority of FDA approved drugs end up being recalled. More people are becoming skeptics than ever before and that, at least, is a positive outcome

Expand full comment

The wake up call is at least necessary.

But DAMN it's an expensive way to go about it!

Expand full comment
Comment deleted
June 30, 2022
Comment deleted
Expand full comment

Bingo. Good catch! Actually, it may be a bit more complicated than as those are the numbers after matching, before matching it is 19.9% vaccinated who took Paxlovid and 24.8% rebounds, and 12.7% vaccinated who took Molnupiravir making up 17.6% of rebound cases. I don't think they have the after matching rates, but the authors did actually notice this, too, and came to the Church of COVID conclusion:

"The EHR-documented COVID-19 vaccination rate was higher in patients with COVID-19 rebound than those without, suggesting that vaccination is not a major contributor to COVID-19 rebound (Table 2). Similar trends were observed for Molnupiravir."

I should make one other note: this could easily be spurious. It seems they only took vaccination status as captured by those who took the vaccine in their EHR meaning the vaccination status of the entire population was likely far higher but they just didn't have data on people that were vaccinated at pharmacies etc

Expand full comment